Drug intelligence / Profile preview

tau mAb

Development stage: Preclinical
Lead developer: Manifold Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

tau mAb (CNS-shuttled) is a preclinical-stage monoclonal antibody being developed by Manifold Bio in collaboration with Roche. It is designed to target the Tau protein, which is associated with neurodegenerative conditions such as Alzheimer's disease and other tauopathies. A key feature of this therapeutic is the integration of a CNS shuttle, a technology designed to facilitate the transport of the antibody across the blood-brain barrier (BBB), thereby increasing its concentration and efficacy within the central nervous system. The program leverages Manifold Bio's M-Design platform to optimize the antibody's properties for brain delivery and target engagement.

Other names: CNS-shuttled Tau mAbTau monoclonal antibody

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on tau mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tau mAb.

Explore the full profile